Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.
about
Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzymeLysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfacesLysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat modelEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRBioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelLysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications.Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactamVancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.Staphylococcus aureus mutants with increased lysostaphin resistance.Endopeptidase and glycosidase activities of the bacteriophage B30 lysinLysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo.In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein.Random mutagenesis identifies novel genes involved in the secretion of antimicrobial, cell wall-lytic enzymes by Lactococcus lactis.Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.Peptidoglycan hydrolases-potential weapons against Staphylococcus aureusMechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.Hydrogen/deuterium exchange mass spectrometry and site-directed disulfide cross-linking suggest an important dynamic interface between the two lysostaphin domains.Identification and structural characterization of LytU, a unique peptidoglycan endopeptidase from the lysostaphin family.In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA)Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.Mutation analysis of the histidine residues in the glycylglycine endopeptidase ALE-1.A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing.
P2860
Q24609957-7249677B-178B-44B6-8835-5D4AE7FFFEE6Q24650674-47675380-A969-4FB8-BBBE-F0A3320A6ED3Q24682172-93B26552-DF2B-4D31-88A5-28B585C91948Q28477900-2C4DD5B3-4405-486D-AE7B-024ABCF97548Q30574330-23F070C1-5E92-43EA-90AA-865ECDB0A9AAQ33593883-D23AB500-0FAF-4126-A030-AFEDAD9F698BQ33664443-D9A84C1A-4FEE-4D2F-91F0-6916C6A9BD95Q33938244-85B1A936-2C14-4DFE-ACE8-4273BE946C16Q33977947-3FE1DBE6-1BD1-47D9-B025-CDF5A057FE4CQ34885043-352B7B7D-1E79-4B7C-849F-3273D9A9FE34Q35075303-198AAA34-1308-4DB9-BA56-A057FE58427CQ35091838-3223A966-BCFB-49EA-BD93-013C634CB174Q35635997-EC841857-8492-454B-A640-088CAAC37A5AQ36911438-D83A07A4-46B6-4630-84B3-20F5097B992DQ37023784-6DDBB761-CB8B-4A45-BDB0-55046DBB0F64Q37733684-42205A58-DE35-4606-9E01-E690A7E630A5Q38053102-906C9327-AEC2-4CBA-B941-298E19E0EF1FQ39477127-FE31F464-E19D-4D07-A22D-637840A3F858Q39651918-43A60A95-3F2C-4BFC-A467-472F2FA695F1Q39740458-65B9C6FD-E79F-4CD7-BE79-015D791D98F7Q39766508-9F9490B1-FFCF-436D-B674-3D5F180E71D5Q40125665-93C22AB6-3F88-4CF5-9885-B5886B8BAEC3Q40130614-D237BE8C-018E-4A00-9AF0-EF6DE5F34D9BQ40427118-F2BE38E9-1445-416F-BE68-2B922BBDC978Q40634630-96236B8A-8548-45DC-A124-99958D986B53Q40875374-60595A79-046D-4332-87EF-FBF74DF20969Q42912582-C95BCB7D-3900-4D6B-808E-A57ECB59FF63Q54212204-683D70E8-0E0A-4767-BB19-1F79F7DD7ADD
P2860
Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@ast
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@en
type
label
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@ast
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@en
prefLabel
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@ast
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@en
P2093
P2860
P1476
Lysostaphin treatment of exper ...... susceptibility to vancomycin.
@en
P2093
B P Goldstein
G L Archer
R L Patron
P2860
P304
P407
P577
1999-07-01T00:00:00Z